Anika Therapeutics, Inc. (ANIK) DCF Valuation

Anika Therapeutics, Inc. (ANIK) Valoración de DCF

US | Healthcare | Medical - Devices | NASDAQ
Anika Therapeutics, Inc. (ANIK) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Anika Therapeutics, Inc. (ANIK) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Ya sea que sea un inversor o analista, esta calculadora DCF (ANIK) es su recurso esencial para una valoración precisa. Cargados con datos reales de Anika Therapeutics, Inc., puede ajustar los pronósticos y observar los efectos en tiempo real.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 114.6 130.5 147.8 156.2 166.7 183.1 201.2 221.1 242.9 266.9
Revenue Growth, % 0 13.83 13.29 5.71 6.67 9.88 9.88 9.88 9.88 9.88
EBITDA 34.2 -12.8 2.6 -4.9 -11.2 4.4 4.8 5.3 5.8 6.4
EBITDA, % 29.88 -9.83 1.77 -3.14 -6.74 2.39 2.39 2.39 2.39 2.39
Depreciation 7.2 15.0 16.0 16.4 14.2 17.4 19.1 21.0 23.1 25.4
Depreciation, % 6.26 11.49 10.82 10.47 8.53 9.51 9.51 9.51 9.51 9.51
EBIT 27.1 -27.8 -13.4 -21.3 -25.4 -13.0 -14.3 -15.8 -17.3 -19.0
EBIT, % 23.63 -21.33 -9.05 -13.61 -15.27 -7.13 -7.13 -7.13 -7.13 -7.13
Total Cash 184.9 98.3 94.4 86.3 72.9 123.9 136.1 149.5 164.3 180.5
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 23.1 24.1 29.8 34.6 36.0
Account Receivables, % 20.14 18.48 20.19 22.16 21.58
Inventories 22.0 46.2 36.0 39.8 46.4 48.4 53.2 58.5 64.3 70.6
Inventories, % 19.19 35.42 24.36 25.45 27.83 26.45 26.45 26.45 26.45 26.45
Accounts Payable 3.8 9.0 7.6 9.1 9.9 9.9 10.9 12.0 13.2 14.5
Accounts Payable, % 3.34 6.89 5.16 5.81 5.92 5.42 5.42 5.42 5.42 5.42
Capital Expenditure -2.8 -1.6 -5.1 -7.5 -5.4 -5.6 -6.1 -6.7 -7.4 -8.1
Capital Expenditure, % -2.47 -1.25 -3.48 -4.79 -3.26 -3.05 -3.05 -3.05 -3.05 -3.05
Tax Rate, % 3.12 3.12 3.12 3.12 3.12 3.12 3.12 3.12 3.12 3.12
EBITAT 20.4 -23.3 -22.8 -16.9 -24.7 -11.4 -12.5 -13.7 -15.1 -16.6
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -16.5 -30.0 -8.8 -15.1 -23.0 -3.1 -7.0 -7.7 -8.4 -9.3
WACC, % 7.94 7.98 8.06 7.95 8.04 7.99 7.99 7.99 7.99 7.99
PV UFCF
SUM PV UFCF -27.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -9
Terminal Value -158
Present Terminal Value -107
Enterprise Value -135
Net Debt -44
Equity Value -91
Diluted Shares Outstanding, MM 15
Equity Value Per Share -6.21

What You Will Get

  • Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Anika Therapeutics’ financial data pre-filled to kickstart your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model designed to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.

Key Features

  • Comprehensive Data Access: Anika Therapeutics’ historical financial statements and projected forecasts.
  • Customizable Parameters: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Insights: View Anika Therapeutics’ intrinsic value update instantly.
  • Intuitive Visualizations: Dashboard graphs illustrate valuation outcomes and essential metrics.
  • Designed for Precision: A reliable tool for analysts, investors, and finance professionals.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Anika Therapeutics, Inc. (ANIK) data.
  • Step 2: Review the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see recalculated results, including Anika Therapeutics, Inc. (ANIK)'s intrinsic value.
  • Step 5: Make well-informed investment decisions or create reports using the generated outputs.

Why Choose Anika Therapeutics, Inc. (ANIK) Calculator?

  • Comprehensive Tool: Features DCF, WACC, and financial ratio analyses tailored for biotech companies.
  • Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios.
  • Detailed Insights: Automatically computes Anika’s intrinsic value and Net Present Value.
  • Preloaded Data: Contains historical and projected data for precise analysis.
  • Professional Quality: Perfect for biotech analysts, investors, and healthcare consultants.

Who Should Use This Product?

  • Investors: Accurately assess Anika Therapeutics’ fair value before making investment choices.
  • CFOs: Utilize a professional-grade DCF model for financial analysis and reporting.
  • Consultants: Easily modify the template for valuation reports tailored to clients.
  • Entrepreneurs: Obtain insights into financial modeling practices employed by leading biotech firms.
  • Educators: Employ it as a teaching resource to illustrate valuation techniques.

What the Template Contains

  • Pre-Filled Data: Includes Anika Therapeutics’ historical financials and forecasts.
  • Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
  • Key Financial Ratios: Analyze Anika Therapeutics’ profitability, efficiency, and leverage.
  • Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
  • Clear Dashboard: Charts and tables summarizing key valuation results.

No products were found matching.